Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma

•Immune checkpoints correlate with higher grade tumours and poor treatment response.•First-line chemotherapies stimulate anti-tumour T cell immunity.•Dual nivolumab-ipilimumab enhances lymphocyte-mediated killing of tumour cells.•Lymphocyte-mediated killing of tumour cells is enhanced by FLOT chemot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational oncology 2022-06, Vol.20, p.101406, Article 101406
Hauptverfasser: Davern, Maria, Donlon, Noel E., O’ Connell, Fiona, Sheppard, Andrew D., Hayes, Conall, King, Ross, Temperley, Hugo, Butler, Christine, Bhardwaj, Anshul, Moore, Jenny, Bracken-Clarke, Dara, Donohoe, Claire, Ravi, Narayanasamy, Reynolds, John V., Maher, Stephen G., Conroy, Melissa J., Lysaght, Joanne
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Immune checkpoints correlate with higher grade tumours and poor treatment response.•First-line chemotherapies stimulate anti-tumour T cell immunity.•Dual nivolumab-ipilimumab enhances lymphocyte-mediated killing of tumour cells.•Lymphocyte-mediated killing of tumour cells is enhanced by FLOT chemotherapy. Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting ‘cold’ tumours into ‘hot’ tumours. This study profiled immune checkpoint (IC) expression on circulating and tumour-infiltrating T cells in OAC patients and correlated these findings with clinical characteristics. The effect of first-line chemotherapy regimens (FLOT and CROSS) on anti-tumour T cell immunity was assessed to help guide design of ICB and chemotherapy combinations in the first-line setting. The ability of ICB to enhance lymphocyte-mediated cytolysis of OAC cells in the absence and presence of post-FLOT and post-CROSS chemotherapy tumour cell secretome was assessed by a CCK-8 assay. Expression of ICs on T cells positively correlated with higher grade tumours and a subsequent poor response to neoadjuvant treatment. First-line chemotherapy regimens substantially altered IC expression profiles of T cells increasing PD-1, A2aR, KLRG-1, PD-L1, PD-L2 and CD160 and decreasing TIM-3 and LAG-3. In addition, pro-inflammatory T cell cytokine profiles were enhanced by first-line chemotherapy regimens. T cell activation status was significantly altered; both chemotherapy regimens upregulated co-stimulatory markers ICOS and CD69 yet downregulated co-stimulatory marker CD27. However, ICB attenuated chemotherapy-induced downregulation of CD27 on T cells and promoted differentiation of effector memory T cells into a terminally differentiated state. Importantly, dual nivolumab-ipilimumab treatment increased lymphocyte-mediated cytolysis of OAC cells, an effect further enhanced in the presence of post-FLOT tumour cell secretome. These findings justify a rationale to administer ICBs concurrently with first-line chemotherapies. Study schematic - (A) Immune checkpoint (IC) expression profiles of T cells in tumour biopsies and whole blood from OAC patients was assessed by flow cytometry and correlated with clinical demographics. (B) The effect of first-line chemotherapy regimens on anti-tumour T cell phenotypes was next assessed using flow cytometry. PBM
ISSN:1936-5233
1936-5233
DOI:10.1016/j.tranon.2022.101406